MR Imaging in Patients at Risk for Developing Nephrogenic Systemic Fibrosis: Protocols, Practices, and Imaging Techniques to Maximize Patient Safety

被引:50
作者
Juluru, Krishna [1 ]
Vogel-Claussen, Jens [2 ]
Macura, Katarzyna J. [2 ]
Kamel, Ihab R. [2 ]
Steever, Alexander [1 ]
Bluemke, David A. [2 ]
机构
[1] Weill Cornell Med Ctr, Dept Radiol, New York, NY 10065 USA
[2] Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, Baltimore, MD USA
关键词
CONTRAST AGENTS; DERMOPATHY; GADOLINIUM; SCLEROMYXEDEMA; DIALYSIS; BASICS; DTPA;
D O I
10.1148/rg.291085072
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Nephrogenic systemic fibrosis (NSF) is a rare but potentially debilitating or even fatal fibrosing condition that most often affects the skin but is now also recognized to involve multiple organs. The first report on NSF was published in 1997, and there is mounting evidence this condition is associated with renal failure and the administration of large amounts of gadolinium. Although gadolinium-enhanced magnetic resonance (MR) imaging was once considered one of the safer imaging procedures, concerns over NSF have led the radiology community to rethink its imaging practices. Several noncontrast angiographic techniques based on fast spin-echo, gradient-echo, phase-contrast, and inversion-recovery principles are currently available. These techniques allow MR angiography to be performed safely, even in patients at risk for developing NSR When use of gadolinium-based contrast material is necessary for diagnosis, it is possible to reduce total gadolinium administration through the use of agents with higher relaxivity, time-resolved imaging, high-field-strength magnets, and body compression devices. Management of NSF also requires an understanding of the risk factors of this disease and developing an institutional policy for identifying and testing at-risk patients.
引用
收藏
页码:9 / 22
页数:14
相关论文
共 30 条
[11]  
*GE HEALTHC, 2007, OMN GAD INJ PACK INS
[12]  
Gibson SE, 2006, ARCH PATHOL LAB MED, V130, P209
[13]   Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? [J].
Grobner, T .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (04) :1104-1108
[14]   PHASE-I CLINICAL-EVALUATION OF GD-EOB-DTPA AS A HEPATOBILIARY MR CONTRAST AGENT - SAFETY, PHARMACOKINETICS, AND MR-IMAGING [J].
HAMM, B ;
STAKS, T ;
MUHLER, A ;
BOLLOW, M ;
TAUPITZ, M ;
FRENZEL, T ;
WOLF, KJ ;
WEINMANN, HJ ;
LANGE, L .
RADIOLOGY, 1995, 195 (03) :785-792
[15]   Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis [J].
High, Whitney A. ;
Ayers, Reed A. ;
Chandler, John ;
Zito, Gary ;
Cowper, Shawn E. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (01) :21-26
[16]   Dialysis-associated systemic fibrosis (Nephrogenic fibrosing dermopathy) -: Study of inflammatory cells and transforming growth factor β1 expression in affected skin [J].
Jiménez, SA ;
Artlett, CM ;
Sandorfi, N ;
Derk, C ;
Latinis, K ;
Sawaya, H ;
Haddad, R ;
Shanahan, JC .
ARTHRITIS AND RHEUMATISM, 2004, 50 (08) :2660-2666
[17]   Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema [J].
Kucher, C ;
Xu, XW ;
Pasha, T ;
Elenitsas, R .
JOURNAL OF CUTANEOUS PATHOLOGY, 2005, 32 (07) :484-490
[18]  
LAUB G, 1994, RADIOLOGE, V34, P416
[19]   Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents [J].
Laurent, Sophie ;
Elst, Luce Vander ;
Muller, Robert N. .
CONTRAST MEDIA & MOLECULAR IMAGING, 2006, 1 (03) :128-137
[20]   MR contrast agents: Physical and pharmacologic basics [J].
Lin, Shao-Pow ;
Brown, Jeffrey J. .
JOURNAL OF MAGNETIC RESONANCE IMAGING, 2007, 25 (05) :884-899